5 news items
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update
CLRB
14 May 24
) patients with a median of four prior lines of therapy. The CLOVER WaM study met its primary endpoint with a major response rate of 61%. The overall response
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
CLRB
27 Mar 24
literature. The CLOVER WaM study met its primary endpoint with a major response rate (MRR) of 61% (95% confidence interval [44.50%, 75.80%, two-sided p
Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's Why
CLRB
4 Mar 24
.
The CLOVER WaM study met its primary endpoint with a major response rate (MRR) of 61%.
The overall response rate (ORR
Cellectar Biosciences Announced That Iopofosine I 131 In Combination With External Beam Radiation Therapy Was Safe And Tolerated In Phase 1 Trial In Recurrent Head And Neck Cancer
CLRB
4 Mar 24
Complete Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
CLRB
4 Mar 24
Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients
- Prev
- 1
- Next